Genes involved in lipid metabolism that are differentially expressed in liver of <i>Fmo5</i>^<i>-/-</i> mice compared with WT mice. by Ian R. Phillips (5074121)

Genes involved in carbohydrate metabolism differentially expressed in liver of <i>Fmo5</i>^<i>-/-</i> mice compared with WT mice. by Ian R. Phillips (5074121)

S5 Fig - by Jordan K. Abbott (8934239)

Inhibition of G9a decreases the tumorigenicity of neuroblastoma cells. by Xiao-Xue Ke (626989)

Magnification X2 of Fig 4A. by Huan W. Yang (19746645)

“…<i>intracellularis</i> bacterial load peaks at 5 dpi. The induction of pro-inflammatory cytokines expression is consistent with the decreased viability of <i>L</i>. …”

Decreasing patterns of P_WT scores in 6 conditions with individual values (0.05, 0.1, 0.2, 0.3, 0.4, and 0.5). by In Seok Yang (4261207)

Echocardiographic measurements in WT and AMPKα2-/- mice following transverse aortic constriction. by Anne Garnier (130125)

Subjects:

Discovery of <i>N</i>‑((3<i>S</i>,4<i>S</i>)‑4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl‑1<i>H</i>‑pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity by Jinxin Che (791250)

Discovery of <i>N</i>‑((3<i>S</i>,4<i>S</i>)‑4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl‑1<i>H</i>‑pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity by Jinxin Che (791250)

Discovery of <i>N</i>‑((3<i>S</i>,4<i>S</i>)‑4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl‑1<i>H</i>‑pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity by Jinxin Che (791250)

Discovery of <i>N</i>‑((3<i>S</i>,4<i>S</i>)‑4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl‑1<i>H</i>‑pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity by Jinxin Che (791250)

Discovery of <i>N</i>‑((3<i>S</i>,4<i>S</i>)‑4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl‑1<i>H</i>‑pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity by Jinxin Che (791250)

Discovery of <i>N</i>‑((3<i>S</i>,4<i>S</i>)‑4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl‑1<i>H</i>‑pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity by Jinxin Che (791250)

Discovery of <i>N</i>‑((3<i>S</i>,4<i>S</i>)‑4-(3,4-Difluorophenyl)piperidin-3-yl)-2-fluoro-4-(1-methyl‑1<i>H</i>‑pyrazol-5-yl)benzamide (Hu7691), a Potent and Selective Akt Inhibitor That Enables Decrease of Cutaneous Toxicity by Jinxin Che (791250)

Variants enriched in an <i>Ae</i>. <i>aegypti</i> cell line <i>(</i>Aag2) have increased fitness in Aag2 cells but decreased fitness in a human cell line (MRC-5). by Chelsea Cereghino (15188341)

Propensity-score matched open aortic group. by Tomi Obafemi (12328433)

“…However, the incidence of post-op ventilator associated pneumonia (VAP) decreased from 5.0% to 2.1% (p = 0.003) and post-op urinary tract infections (UTIs) from 8.3% to 3.6% (p<0.001). …”

Pre-match open aortic group. by Tomi Obafemi (12328433)

“…However, the incidence of post-op ventilator associated pneumonia (VAP) decreased from 5.0% to 2.1% (p = 0.003) and post-op urinary tract infections (UTIs) from 8.3% to 3.6% (p<0.001). …”

Pre-match CABG/Valve group. by Tomi Obafemi (12328433)

“…However, the incidence of post-op ventilator associated pneumonia (VAP) decreased from 5.0% to 2.1% (p = 0.003) and post-op urinary tract infections (UTIs) from 8.3% to 3.6% (p<0.001). …”

Propensity-score matched CABG/Valve group. by Tomi Obafemi (12328433)

“…However, the incidence of post-op ventilator associated pneumonia (VAP) decreased from 5.0% to 2.1% (p = 0.003) and post-op urinary tract infections (UTIs) from 8.3% to 3.6% (p<0.001). …”

Image_1_IL-1β enhances cell viability and decreases 5-FU sensitivity in novel colon cancer cell lines derived from African American patients.tif by Marzia Spagnardi (9330602)

“…When compared to Caucasian American (CA) patients, AAs also have reduced response to the first line standard of care chemotherapeutic agent 5-Fluorouracil (5-FU). Previously, we observed differential gene expression between the two populations, suggesting that colon tumors from AA patients display a decreased antitumor immune response and an increased expression of genes encoding proteins involved in inflammatory processes, such as Interleukin-1β (IL-1β). …”